Objective-In search of molecular imaging modalities for specific detection of inflammatory atherosclerotic plaques, we explored the potential of targeting scavenger receptor-AI (SR-AI), which is highly expressed by lesional macrophages and linked to effective internalization machinery. Approach and Results-Ultrasmall superparamagnetic iron oxide particles were conjugated to a peptidic SR-AI ligand (0.371 mol Fe/L and 0.018 mol PP1/L). In vitro incubation of human or murine macrophages with SR-AI-targeted USPIO led to significantly higher iron uptake in vitro than with nontargeted USPIO, as judged by quantitative atomic absorption spectroscopy and Perl's staining. Incremental uptake was strictly mediated by SRs. SR-AI-targeted USPIO displayed accelerated plasma decay and a 3.5-fold increase (P=0.01) in atherosclerotic plaque accumulation on intravenous injection into apolipoprotein E-deficient mice compared with nontargeted USPIO. In addition, atherosclerotic humanized LDLr −/− chimeras with leukocyte expression of human SR-AI showed a significant improvement in contrast-to-noise ratio (2.7-fold; P=0.003) in the atherosclerotic aortic arch plaques 24 hours after injection of SR-AI-targeted USPIO compared with chimeras with leukocyte SR-AI deficiency.
D espite recent advances in our understanding of the pathogenesis of acute cardiovascular syndromes, current imaging diagnostic methods lack the desired specificity to identify those atherosclerotic plaques that are at risk of becoming clinically symptomatic. Noninvasive detection methods, such as MRI, have shown to enable early tracking of subclinical lesions, characterization of plaque composition, and accurate discrimination between stable and unstable lesions. Superparamagnetic contrast agents, for example, ferumoxtran-10, an ultrasmall superparamagnetic iron oxide nanoparticle (USPIO), have been developed to augment signal sensitivity and are to date widely used as contrast agents for molecular and cellular imaging 1 and have been applied for detection of metastases, 2,3 multiple sclerosis lesions, 4, 5 inflammatory foci in the central nervous system, 6 and atherosclerotic plaques. 7, 8 USPIO particle clearance mainly occurs via nonspecific receptor-mediated endocytosis 9 by monocytes/macrophages, referred to as passive targeting, and as a result of this long circulation time end up in lymph node macrophages and peripheral tissue macrophages. 10, 11 Different cell types in the atherosclerotic plaques highly express class A scavenger receptors (SR-A), which have been suggested to play a crucial role in atherogenesis. [12] [13] [14] [15] Scavenger receptor-mediated uptake of modified lipoproteins is deemed instrumental in foam cell formation and activation, promoting a proinflammatory phenotype of lesional macrophages. 16 Abundant SR expression was found in lesion-specific foam cells and vascular smooth muscle cells (VSMCs) of advanced inflammatory plaques, but not in the healthy vessel wall, 17, 18 and is associated with efficient receptor-mediated endocytosis. This qualifies SR-AI as promising target for plaque-directed molecular imaging and drug delivery approaches by improving uptake and signal intensity compared with passive targeting.
We recently identified a 16-mer peptide PP1 (LSLERFLRCWSDAPAK) by phage display library screening that displayed high affinity and specificity for SR-AI in vitro in murine and human macrophages. In vivo, PP1 has been shown to accumulate in macrophage-rich organs where it colocalized with F4/80+ macrophages and in atherosclerotic plaques. Furthermore, intravenous injected PP1-coupled fluorescent nanocrystals were successfully accumulated in advanced atherosclerotic plaques of apolipoprotein E-deficient (apoE −/− ) mice. 19 In the current study, we report development and validation of SR-AI-targeted USPIO (T-USPIO) functionalized with the aforementioned SR-AI-specific peptide. The T-USPIO was validated in vitro on different mouse and human cell types found in atherosclerotic lesions and also in vivo in an established mouse model for atherosclerosis, as well as in a humanized model of atherosclerosis.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Relaxivity Analysis
The contrast agent relaxivities were measured at 37°C at 20, 60, and 400 MHz, respectively (Table) . The transverse relaxivities of the SR-A1 and control particle did not differ significantly nor did the longitudinal relaxivity.
Increased Scavenger Receptor-AI-Mediated Uptake of T-USPIO In Vitro
The kinetics of basal uptake, processing, and detection of USPIO in vitro and in vivo by macrophages have been the subject of numerous studies. 9 Here, we sought to investigate whether USPIO uptake by (plaque associated) macrophages could be augmented by conjugation to a newly devised peptide ligand for SR-AI ( Figure 1A ), 19 a receptor previously shown to be highly expressed by this leukocyte subset in inflammatory foci within the plaque. 20 As a measure of USPIO uptake by RAW264.7 cells (300 μg Fe/mL), cell-associated iron was assessed using quantitative atomic absorption spectroscopy analysis. SR-AI T-USPIO showed a markedly increased uptake by macrophages than non-T-US-PIO (1729±152 versus 805±111 ng Fe/g cell pellet; P<0.001; Figure 2A ). In vitro uptake studies in human THP-1 and U937 macrophages revealed a comparable 2-fold increase in cellular uptake of T-USPIO over USPIO (P=0.01). In both human THP-1 and U937 macrophages, T-USPIO uptake could be significantly reduced in the presence of fucoidan, an established broad-spectrum inhibitor of SR-AI/II ( Figure 2B and 2C). 21 Furthermore, coincubation with a specific SR-AI inhibitor dG 16 , but not dG 3 T 13 (the nonbinding analog), 22 decreased T-USPIO accumulation to similar extent as observed with fucoidan ( Figure 2C ). These data further establish the specificity of T-USPIO for SR-A1. Interestingly, T-USPIO also showed increased accumulation by VSMCs to levels comparable with that of macrophages, suggesting that VSMCs as well are capable of phagocytosing the T-USPIO. Incubation of endothelial cells with USPIO and T-USPIO led to basal iron accumulation, similar to or lower than with non-T-USPIO in macrophages ( Figure 2D ).
Increased T-USPIO accumulation by THP-1 cells was translated in a decreased MRI T2 relaxation time (65.4±0.6 ms; P=0.01) compared with cells incubated with USPIO (72.5±1.4 ms; Figure 2E ). Again, incubation with fucoidan neutralized the decrease in T2 relaxation of T-USPIO, albeit to a lesser extent also of USPIO-incubated macrophages. In fact, T2 relaxation times after fucoidan treatment were comparable with that of the control samples. In keeping with these in vitro MRI data, Perl's staining of THP-1 macrophages confirmed the more abundant presence of iron deposits in T-USPIOincubated macrophages ( Figure 2F and 2G). Our results thus indicate that peptide T-USPIO displays significantly increased SR-AI-dependent uptake by macrophages in vitro.
Increased Plasma Clearance and Increased Signal In Vivo on Targeted Delivery of USPIO in ApoE −/− Mice
As a next step, we investigated the optimal imaging window and the fate of plaque accumulation of the SR-AI-targeted T-USPIO in vivo in aged (1 year) apoE −/− mice (n=14) with established advanced atherosclerotic lesions. Mice were imaged every 30 minutes for the first 3 hours after contrast agent injection and thereafter followed every 2.5 hours until 48 hours after injection. USPIO and T-USPIO accumulation increased gradually in the plaque on the inner curvature of the aortic arch, and maximum accumulation and contrast-to-noise ratio (CNR) were observed 24 hours after injection.
A subset of mice received a single intravenous injection with T-USPIO (250 μmol Fe/kg; n=6), whereas the control group received plain USPIO (250 μmol Fe/kg; n=6). The remaining mice were used to determine endogenous tissue iron content. Kinetic analysis of plasma iron levels by inductively coupled plasma atomic emission spectroscopy ( Figure 3A) pointed to an increased plasma clearance of T-USPIO (T 1/2 =1.7 hours) compared with USPIO (T 1/2 =2.9 hours; P<0.05). Plasma iron levels declined to baseline within 24 hours after administration of T-USPIO or USPIO. Analysis of macrophage-rich organs, such as liver, spleen, and lungs, as well as kidney 24 hours after injection ( Figure 3B ), showed increased iron accumulation in liver, the primary eliminating organ, in USPIO (3.1±0.3 μmol Fe/g; NS) and even more so in T-USPIO-treated mice (3.4±0.4 μmol Fe/g tissue; P<0.05) compared with the endogenous tissue iron concentrations (1.6±0.3 μmol Fe/g). In vivo MRI of the aortic arch 24 hours after injection of contrast agent revealed increased accumulation of T-USPIO compared with non-T-US-PIO in atherosclerotic plaques on the basis of the inner curvature Figure 4A -4C). Except for liver, biodistribution profiles of T-USPIO and USPIO were essentially similar and did not significantly differ from that of untreated controls ( Figure 3B ). Lesion-prone artery segments (aortic valve area, Figure 4 ) were also analyzed ex vivo for lesion size, monocyte/ macrophage content (MoMa-2), and iron accumulation. CNR increase could neither be attributed to differences in lesion size ( Figure 4J 
T-USPIO Show Superior Accumulation in Plaques in a Humanized Mouse Model of Atherosclerosis
In initial studies, we already showed that the SR-AI targeting peptide PP1 had higher affinity for human-derived THP-1 macrophages than for murine macrophages, suggesting that PP1 may be, at least, equally effective in a human setting. 19 To address its potential for human plaque imaging, we generated LDLr −/− chimeras with hematopoietic human SR-AI expression by bone marrow transplantation (>90% bone marrow reconstitution after 6 weeks). Chimeras with hematopoietic SR-AI deficiency (SR-AI −/− ) and wild-type bone marrowtransplanted LDLr −/− mice served as control. After a recovery period of 6 weeks, atherogenesis was induced by Western-type diet feeding (18 weeks). All groups of mice received a single intravenous dose of PP1-targeted contrast agent (T-USPIO; 250 μmol Fe/kg). After 24 hours, mice were anesthetized and subjected to in vivo MRI at 9.4 T. In keeping with previous findings 23,24 morphometric analysis did not reveal any differences in plaque size between SR-AI −/− and human SR-AI mice ( Figure 5G-5I ; representative pictures of the Oil Red O staining) Importantly, plaque monocyte/macrophage content of the atherosclerotic lesions also did not differ ( Figure 5D-5F ).
In vivo MRI analysis of the aortic arch revealed a significantly decreased CNR in mice overexpressing human SR-AI (−17.4±2.3) compared with SR-A −/− controls (−6.4±0.5; P=0.004) and wildtype bone marrow animals ( Figure 5A-5C ). Furthermore, the signal voids in MR images pointed to augmented iron uptake in human SR-AI-overexpressing mice. These results clearly illustrate the improved capacity of SR-AI-targeted contrast agents to accumulate in atherosclerotic lesions in an SR-AI dependent manner.
Discussion
The data of current study show that conjugation of PP1 to USPIO particles could provide a useful molecular imaging tool for noninvasive imaging of atherosclerotic plaques. We not only show increased accumulation of this PP1-conjugated USPIO by the major plaque phagocytic cells, macrophages and VSMCs, in vitro and in vivo in advanced atherosclerotic lesions in apoE −/− mice, but also enhanced MR image contrast in advanced atherosclerotic plaques in a humanized model of atherosclerosis.
USPIO particles have been used in noninvasive clinical imaging to enhance image contrast in detection of malignancies, 25 inflammatory multiple sclerosis lesions, central nervous system pathologies, and atherosclerotic lesions. 7 One of the major challenges in cardiovascular imaging is the clinically relevant distinction between stable and unstable rupture-prone lesions. The abundant presence of macrophages is a hallmark feature of the latter plaques. 26 This renders macrophages primary targets in diagnostic strategies for vulnerable plaque detection. The current study provides several lines of evidence for effective SR-A1-directed targeting of plaque macrophages. First, USPIO particles, equipped with the SR-A1-specific peptide ligand PP1, T-USPIO, show preferential and SR-AI-dependent uptake by murine and human macrophages in vitro. However, from our data, we observed some additional phagocytic activity of VSMCs for T-USPIO in vitro. Second, T-USPIO had accelerated plasma decay and augmented accumulation by atherosclerotic plaques in aged apoE −/− mice and in Western-type diet-fed LDLR −/− with human SR-AI. Third, T-USPIO was capable of visualizing inflammatory aortic arch plaques by MRI in vivo.
The marked expression of SR-AI in macrophage-enriched sites of inflammation and the fact that this receptor mediates efficient endocytosis of its substrates render it an interesting candidate for targeted delivery to macrophage-rich inflammatory plaques. 12, 27, 28 Recently, our group successfully identified a small 16-mer peptide (PP1) with high specificity and affinity for SR-AI, a promising homing device for contrast agents. 19 Concordant with our previous study, PP1-conjugated USPIO was preferentially taken up by macrophages and VSMCs. Phagocytosis occurred in an SR-dependent manner because SR-AI inhibitor (fucoidan and dG 16 ) coincubation blunted the incremental uptake, which was not observed by a partial SR-AI inhibitor (dG 3 T 13 ). Phagocytosis of conventional USPIO was partly inhibited as well, fueling the notion that SR-A may to some extent also contribute to untargeted USPIO uptake. 9 Further support for SR-AI specificity was derived from the sharply diminished in vivo accumulation of T-USPIO in LDLr −/− chimeras deficient in leukocyte SR-AI. 23 Another important issue is whether the capacity T-USPIO to target plaque phagocytotic activity in mice will be fully reflective of its targeting efficacy in a human context. Our data in a humanized model of atherosclerosis (ie, LDLr −/− mice with macrophage-specific overexpression of the human macrophage SR-A) 24,29,30 clearly confirm the imaging potential of PP1-equipped USPIO for human inflammatory plaques. From histological plaque analysis, we can exclude differences in lesion size or plaque characteristics between the different groups, confirming that the increased image contrast is attributable to increased T-USPIO ingestion by SR-AI-expressing plaque macrophages.
Although the targeting efficacy of T-USPIO in human SR-A1→LDLr −/− chimeras and apoE −/− was largely the same, we did notice minor differences. These may well relate to issues other than species differences in SR-AI receptor binding, such as progression stage of lesions (higher in apoE −/− ), the level of neovascularization (higher in apoE −/− ), 31 plaque inflammation, and cap fibrosis, all of which potentially affect the penetration of T-USPIO particles into the plaque. 32 The biodistribution profile of T-USPIO was consistent with that of [ 125 I]-labeled PP1. 19 The faster plasma decay of T-USPIO and increased hepatic uptake relative to USPIO, likely because of accelerated elimination by SR-A1 on liver cells and endothelial cells, 33 will have beneficial and adverse effects on plaque imaging. On the one hand, it may constrain the penetration of T-USPIO into the plaque and may enhance USPIO deposition in cells of the reticulo-endothelial system for metabolic degradation, with the associated risk of toxicity. 34 On the other hand, it may be accompanied by even faster normalization of blood signal intensity and will reduce nonspecific USPIO accumulation by surrounding tissue, which both will augment CNR in the vessel wall. With regard to the latter, it will be of great interest for future studies to optimize the circulation time of the particles for maximum specificity and minimum toxicity, for example, by using larger iron oxide particles (in vivo MRI of acute brain inflammation using microparticles of iron oxide). 35 Several reports have been published so far on targeted imaging of inflammation and of vulnerable atherosclerotic plaques. Macrophages remain an important target for imaging as they are key effectors in atherosclerosis, 26 and their high abundance in plaque was associated with a high risk of clinical complications. [36] [37] [38] Currently, 2 major approaches exist for imaging intraplaque macrophage density. Macrophages have been targeted in a passive manner, be it after penetration of USPIO into the plaque and ingestion in situ or via circulating USPIO-laden monocytes which after plaque invasion differentiate into macrophages. 39 Alternatively, for molecular imaging of inflammatory plaques the potential of active targeting of plaque leukocyte subsets 40 has been explored, often using SRs as route of entry. 41, 42 Synthetic PP1 may contrast favorably to the homing devices used in the latter studies. It shows a similar to even higher in vivo accumulation ratio than macrophage-targeted immunomicelles, 43 malondialdehyde-2, 44 oxidized low-density lipoprotein-targeted 44 and tyrosine polyethylene glycol micelles, 45 and high-density lipoprotein-based contrast agent. 46 Although at least equally effective and synthetically flexible, these peptide-based homing vehicles display higher receptor specificity (compared with polyethylene glycol micelles, high-density lipoprotein-based contrast agents), are less immunogenic (compared with malondialdehyde-2 micelles, synthetic high-density lipoprotein), or do not give rise to cell activation (compared with liposomes). 47 PP1-equipped contrast agents (positron emission tomography or MRI) may thus represent an effective tool to visualize SR-AI-dependent phagocytic activity in atherosclerotic lesions in the patient at risk. How SR-directed imaging of inflammatory atherosclerotic plaques compares with that of the imaging of other vulnerable plaque components or processes, such as apoptosis, necrosis, neovascularization, extracellular matrix, and matrix metalloproteinases, 48 remains to be investigated.
In conclusion, we here show the successful development of an SR-AI-targeted iron oxide-based MRI contrast agent that shows increased and SR-AI-dependent accumulation by both macrophages and VSMCs, in vitro as well as in vivo in an established atherosclerotic mouse model. The SR-AI T-USPIO combines rapid blood decay with effective phagocytotic uptake by atherosclerotic plaques because of its high affinity for SR-AI. Importantly, T-USPIO displayed favorable CNR in MRI-aided detection of atherosclerotic plaques in a mouse model with murine as well as with human SR-AI expression. In vivo MRI of the aortic arch reveals increased lesional uptake of targeted ultrasmall superparamagnetic iron oxide (USPIO) in human scavenger receptor A (hSR-A)-overexpressing LDLr −/− chimeras. After bone marrow transplantation, LDLr −/− chimeras were fed a high cholesterol diet to induce atherosclerotic plaque formation. SR-A −/− , hSR-A-overexpressing, and wild-type (control) bone marrow recipients received a single administration with targeted USPIO. At 24 hours after injection, mice were subjected to in vivo MRI and subsequently euthanized. Contrast-to-noise ratio (CNR) was determined by computer-assisted analysis of MR images (A-C). For each mouse, 3 images were analyzed and mean CNR was determined (C). Cryosections were made from the atherosclerotic lesion-prone aortic root and subsequently stained (MoMa-2; E and F and Oil Red O; H and I) and analyzed for MoMa-2 (D) and for atherosclerotic plaque size (G). Data are shown as mean±SEM (**P<0.01).
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